Boston Scientific warns physicians of a potential defect in its unique subcutaneous implantable cardioverter defibrillators.
Boston Scientific (NYSE:BSX) recently issued a warning on its lead-free implantable defibrillators over concerns that a fuse malfunction could prevent the devices from delivering life-savings shocks, the company confirmed with MassDevice.com today.
The company has received reports of 4 instances in which a fuse inside the subcutaneous ICD was activated inappropriately, which could cause the devices to fail. No adverse events have yet been reported, according to Boston Scientific.
